Source MS Society: Last year, we announced a new trial testing if a drug called cladribine can slow down the worsening of arm and hand movement for people with advanced primary or secondary progressive MS.
Source MS Society: Today, 6th August 2021, a painter from Bromley will become the first person to join ChariotMS, a new clinical trial focusing on advanced MS.
Last year, we announced a new trial testing if a drug called cladribine can slow down the worsening of arm and hand movement for people with advanced primary or secondary progressive MS.
After some delays due to COVID-19, today Carol Allen will become the first person to officially join the trial.
Carol, 70, lives with primary progressive MS and uses a wheelchair to get around.
Receiving the first dose of the drug or placebo
At today’s visit to the lead trial site in London, Carol will receive her first tablet of either cladribine or a dummy drug (placebo). Neither she nor the trial team will know which one she is taking.
She’ll do some tests too. Like the Nine Hole Peg Test, which involves putting pegs into holes as quickly as possible. By repeating the tests several times throughout the trial, the team can measure how hand and arm function changes over time. So they can work out if cladribine slows progression better than the placebo. Read on.
